Comerica (CMA) - FREE Research Report

Killian John M who is EVP - Chief Credit Officer at Comerica sold 1,737 shares at $47.60 on Feb. 20, 2014. Following this transaction, the EVP - Chief Credit Officer owned 32,020 shares meaning that the stake was reduced by 5.15% with the 1,737-share transaction.

The shares most recently traded at $46.51, down $1.09, or 2.35% since the insider transaction. Historical insider transactions for Comerica go as follows:

  • 4-Week # shares sold: 25,850
  • 12-Week # shares sold: 25,850
  • 24-Week # shares sold: 25,850

The average volume for Comerica has been 1.3 million shares per day over the past 30 days. Comerica has a market cap of $8.5 billion and is part of the financial sector and banking industry. Shares are down 1.75% year-to-date as of the close of trading on Thursday.

Affiliated with SPP. Syndicating mostly asset-covered deals. Will go through SPP on most cash-flow oriented transactions. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 16.4. Currently there are 3 analysts that rate Comerica a buy, 7 analysts rate it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMA - FREE

TheStreet Quant Ratings rates Comerica as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, solid stock price performance, reasonable valuation levels and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Comerica Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Wireless Carriers Offer Deals to Connect Apple Watch 3 to Their Networks

Apple's Next Big Ambition Might Not Generate Any Revenue Just Yet

Here's How Apple Could Surprise Us With an Improved Apple Watch

How Much Trouble is Aetna in After Its HIV Status Breach?

Healthcare Management Stocks Look Too Pricey for Activists